Abstract:Abstract Background: Both Ductal Adenocarcinoma (DAC) and Intraductal Carcinoma (IDC) of the prostate are generally associated with aggressive clinical behavior and poor prognosis and can be lethal. Furthermore, previous studies linked aggressive clinical behavior and poor prognosis with discordant FDG positivity and low Prostate-specific membrane antigen (PSMA) expression. A recent study only cited a DAC patient with low 68Ga-PSMA-11 PET/CT uptake but high 18F-FDG PET/CT uptake, however, there is lack of directly compared articles nor large data sets. IDC-P has similar cribriform pattern in the pathological structure as a mean differential diagnosis for DAC. Hence, the objective of this study was to investigate the expression of PSMA and GLUT1 in DAC and IDC-P patients. Methods: The study was conducted on 87 DAC or IDCP patients without any treatment and 97 PAC patients with a Gleason score ≥ 8 of prostate biopsies and prostatectomy samples between August 2017 and August 2022. We performed immunohistochemical staining and scoring of various cancer component samples from the patients to reflect the protein expression levels of PSMA and GLUT1. Results: PSMA expression in PAC tissues was significantly higher than in DAC/IDC-P tissues (141.2 vs 78.6, p < 0.001). There was no significant difference in PSMA membrane expression between DAC/IDC-P and adjacent acinar adenocarcinoma (78.6 vs 93.4, p = 0.166). GLUT1 expression was higher in DAC/IDC-P tissue than in acinar adenocarcinoma tissue adjacent to DAC/IDC-P (68.6 vs 51.3, p = 0.007), but was still lower than that in PAC tissue (68.6 vs 93.1, p = 0.0014). It is worth noting that GLUT1 membrane expression in DAC/IDC-P was significantly increased than in PAC (13.0 vs 6.6, p = 0.025), and in acinar adenocarcinoma adjacent to DAC/IDC-P (13.0 vs 2.0, p < 0.001). Conclusions: In DAC and IDC-P tissues, PSMA membrane expression is low, while GLUT1 expression, especially GLUT1 membrane expression is high. These findings imply that DAC and IDC-P cells may have higher glucose metabolic and raise interest in targeting membrane GLUT1 as a novel anticancer strategy for DAC/IDC-P and other prostate cancer with high glucose metabolism. Citation Format: Xingming Wang, Xiaomei Gao, Lin Qi, Ye Zhang, Hongling Yin, Yu Gan, Yi Cai. High GLUT1 membrane expression and low PSMA membrane expression in ductal adenocarcinoma and intraductal carcinoma of the prostate [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C090.

Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens

Comparative study of clinical and imaging features of pancreatic adenosquamous carcinoma and pancreatic ductal adenocarcinoma

Genetic profile of ductal adenocarcinoma of the prostate

Construction and validation of a prognostic nomogram for ductal adenocarcinoma of the prostate: A population-based study

Mucinous Prostate Cancer Shows Similar Prognosis To Typical Prostate Acinar Carcinoma: A Large Population-Based And Propensity Score-Matched Study

Ductal Adenocarcinoma Of The Prostate: Immunohistochemical Findings And Clinical Significance

Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score–matching Study

Ductal, Intraductal, and Cribriform Carcinoma of the Prostate: Molecular Characteristics and Clinical Management

Diagnosis and Management of Prostatic Ductal Adenocarcinoma

Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma

The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.

Ductal adenocarcinoma of the prostate: clinical analysis of 8 cases

Oncological Outcomes Of Patients With Ductal Adenocarcinoma Of The Prostate Receiving Radical Prostatectomy Or Radiotherapy

Abstract C090: High GLUT1 Membrane Expression and Low PSMA Membrane Expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the Prostate

Prognostic Values of Clinicopathological Characteristics and Survival Outcomes in Prostate Infiltrating Ductal Carcinoma: a Population-Based Study

Ductal prostate cancer staging: Role of PSMA PET/CT

Does Ductal Adenocarcinoma of the Prostate (DA) Have Any Prognostic Impact on Patients with De Novo Metastatic Prostate Cancer?

Intraductal Carcinoma of the Prostate in Prostate Biopsy Samples: Correlation with Aggressive Pathological Features after Radical Prostatectomy and Prognostic Value in High-Risk Prostate Cancer

High GLUT1 Membrane Expression and Low PSMA Membrane Expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the Prostate

Distinct Genomic Features and Evolutionary Relationships Between Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.

The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with de Novo Metastatic Prostate Cancer.